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1. Introduction 
1.1. Origin and epidemiology 
Dengue virus (DENV) is a member of the Flavivirus genus within the family of the 
Flaviviridae and is the most common mosquito-borne viral disease. Flaviviruses derived 
from a common viral ancestor 10,000 years ago. DENV has a relative recent 
revolutionary history originating 1000 years ago and establishes transmission in humans 
since a few hundred years. There is strong evidence that DENV was originally a monkey 
virus in non-human primates in Africa and Asia. Cross-species transmission to humans 
has occurred independently for all four DENV serotypes [1,2]. Each serotype shares 
around 65% of the genome and despite of the differences, each serotype causes nearly 
identical syndromes in humans and circulates in the same ecological niche [3]. First 
clinical symptoms of dengue infections date from the 10th century but it is not for sure 
that this was a dengue epidemic. The first large dengue epidemics were in 1779 in  
Asia, Africa and North America. The first reported epidemic of dengue hemorrhagic 
fever (DHF) was in Manilla, Philippines, in 1953 after World War II. It was suggested 
that he movement of the troops during World War II has led to the spread of the virus. It 
has been shown that in the 19th and 20th century, the virus was widespread in the tropics 
and subtropics where nowadays 3.6 billion people are at risk of getting infected with 
DENV (Figure 1). Every year, 50 million infections occur, including 500,000 
hospitalizations for DHF, mainly among children, with a case fatality rate exceeding 15% 
in some areas [4,5]. In 40 years of time, DENV became endemic in more than 100 
countries because of the increase in human population, international transport and the 
lack of vector control. 
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Figure 1. Global distribution of dengue virus infections in 2011. Contour lines represent the areas at 
risk (Source: WHO, 2012). 
1.2. Transmission 
The transmission of DENV can only occur by the bite of an infected female mosquito, the 
Aedes aegypti and the Aedes albopictus. Aedes aegypti originated, and is still present, in the 
rainforests of Africa feeding on non-human primates (sylvatic cycle, Figure 2). DENV 
infection in non-human primates occurs asymptomatically. However, the mosquito became 
domesticated due to massive deforestation and breeds in artificial water holdings, like 
automobile tires, discarded bottles and buckets that collect rainwater [4]. On one hand Aedes 
aegypti is not an efficient vector because it has a low susceptibility for oral infection with 
virus in human blood. Since mosquitoes ingest 1 µl of blood, the virus titer in human blood 
has to be 105-107 per ml for transmission to be sustained. After 7-14 days the virus has 
passed the intestinal tract to the salivary glands and can be transmitted by the infected 
mosquito to a new host. On the other hand, Aedes aegypti is an efficient vector because it has 
adapted to humans and they repeatedly feed themselves in daylight on different hosts. After 
a blood meal, the oviposition can be stimulated and the virus can be passed transovarially to 
the next generation of mosquitoes (vertical transmission, Figure 2) [6].  
The tiger mosquito Aedes albopictus is spreading his region from Asia to Europe and the 
United States of America (USA). In the 1980s, infected Aedes Albopictus larvae were 
transported in truck tires from Asia to the United States. Dengue viruses were introduced 
into port cities, resulting in major epidemics [6]. 
Because there is no vaccine available, the only efficient way to prevent DENV infection is 
eradication of the mosquito. In the 1950s and 1960s there was a successful vector control 
program in the USA organized by the Pan American Health Organization. They eradicated the 
mosquito from 19 countries. Unfortunately, the vector control program was stopped in 1972 
because the government thought that DENV was not important anymore [2,4]. This resulted in 
a re-emergence of the mosquito and DENV infections in the USA. Both demographic and 
ecological changes contributed to the world wide spread of DENV infections. 
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Figure 2. Transmission of DENV by Aedes mosquitoes. Modified from Whitehead et al. [7]. 
Very recently, another approach to attack the vector has been documented [8,9]. There was a 
mosquito made resistant to DENV infection after trans infection with the endosymbiont 
Wolbachia bacterium which can infect a lot of insects. A certain strain of the Wolbachia 
bacteria was trans infected in Aedes mosquitoes and was reported to inhibit the replication 
and dissemination of several RNA viruses, such as DENV. Embryos of a Wolbachia 
uninfected female die if the female has bred with a Wolbachia infected male. This means that 
Wolbachia infected mosquitoes can take over the natural population. This was recently tested 
in Australia, where dengue is endemic, and after 2 months the Wolbachia infected 
mosquitoes resistant to DENV had taken over the natural mosquito population. Thus, this 
indicates the beginning of a new area in vector control efforts with a high potential to 
succeed. 
1.3. Pathogenesis 
Although DENV infections have a high prevalence, the pathogenesis of the disease is not 
well understood. The disease spectrum can range from an asymptomatic or flu like illness to 
a lethal disease. After a bite of an infected mosquito, there is an incubation period of 3 to 8 
days. Then there is on acute onset of fever ( ≥ 39°C) accompanied by nonspecific symptoms 
like severe headache, nausea, vomiting, muscle and joint pain (dengue fever). Clinical 
findings alone are not helpful to distinguish dengue fever from other febrile illnesses such 
as malaria or measles. Half of the infected patients report a rash and is most commonly seen 
on the trunk and the insides of arms and thighs. Skin hemorrhages, including petechiae and 
purpura, are very common. Liver enzyme levels of alanine aminotransferase and aspartate 
aminotransferase can be elevated. Dengue fever is generally self-limiting and is rarely fatal 
[5,10,11]. 
The disease can escalate into dengue hemorrhagic fever (DHF) or dengue shock syndrome 
(DSS). DHF is primarily a children’s disease and is characterized as an acute febrile illness 
with thrombocytopenia (≤ 100,000 cells/mm3). This results in an increased vascular 
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permeability and plasma leakage from the blood vessels into the tissue. Plasma leakage has 
been documented by an increased hematocrit and a progressive decrease in platelet count. 
Petechiae and subcutaneous bleedings are very common [12]. 
DSS is defined when the plasma leakage becomes critical resulting in circulatory failure, 
weak pulse and hypotension. Plasma volume studies have shown a reduction of more than 
20% in severe cases. A progressively decreasing platelet count, a rising hematocrit, sustained 
abdominal pain, persistent vomiting, restlessness and lethargy may be all signs for DSS. 
Prevention of shock can only be established after volume replacement with intravenous 
fluids [5,11]. When experienced clinicians and nursing staff are available in endemic areas, 
the case fatality rate is < 1%. 
DHF and DSS occur during a secondary infection with a heterologous serotype. The first 
infection with one of the four serotypes provides lifelong immunity to the homologous 
virus. During a second infection with a heterologous serotype, non-neutralizing IgG 
antibodies can enhance disease severity. This phenomenon is called antibody-dependent 
enhancement (ADE). The pre-existing non-neutralizing heterotypic antibodies can form a 
complex with DENV and enhance the access to Fc-receptor bearing cells such as monocytes 
and macrophages [13,14] (Figure 3).  
 
Figure 3. Mechanism of antibody-dependent enhancement (ADE). During a secondary infection caused 
by a heterologous virus, the pre-existing heterotypic antibodies can cross-react with the other DENV 
serotypes. The non-neutralizing antibody-virus complex can interact with the Fc-receptor on monocytes 
or macrophages. This will lead to an increased viral load and a more severe disease. Figure derived 
from Whitehead et al. [7]. 
This will lead to an increase in viral load and a more severe disease. These non-neutralizing 
antibodies can cross-react with all four virus serotypes, as well as with other flaviviruses. 
This phenomenon explains why young infants born to dengue immune mothers often 
experience a more severe disease due to transplacental transfer of DENV-specific antibodies 
[15]. Another approach to assist this phenomenon is the observation of increased viremia in 
non-human primates which received passive immunization with antibodies against DENV 
[16]. 
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A second mechanism to explain ADE of flaviviruses is the involvement of the complement 
system. It has been shown that monoclonal antibodies against complement receptor 3 inhibit 
ADE of West Nile virus in vitro [14]. But Fc-receptor-dependent ADE is believed to be the 
most common mechanism of ADE. 
2. DENV entry 
2.1. Entry process 
The infectious entry of DENV into its target cells, mainly dendritic cells [17], monocytes and 
macrophages, is mediated by the viral envelope glycoprotein E via receptor-mediated 
endocytosis [18]. The E-glycoprotein is the major component (53 kDa) of the virion surface 
and is arranged as 90 homodimers in mature virions [19]. Recent reports demonstrated also 
that DENV enters its host cell via clathrin-mediated endocytosis [20,21], as observed with 
other types of flaviviruses [22,23]. Evidence for flavivirus entry via this pathway is based on 
the use of inhibitors of clathrin-mediated uptake, such as chlorpromazine. However, DENV 
entry via a non-classical endocytic pathway independent from clathrin has also been 
described [24]. It seems that the entry pathway chosen by DENV is highly dependent on the 
cell type and viral strain. In case of the classical endocytic pathway, there is an uptake of the 
receptor-bound virus by clathrin coated vesicles. These vesicles fuse with early endosomes 
to deliver the viral RNA into the cytoplasm. The E-protein responds to the reduced pH of 
the endosome with a large conformational rearrangement [25,26]. The low pH triggers 
dissociation of the E-homodimer, which then leads to the insertion of the fusion peptide into 
the target cell membrane forming a bridge between the virus and the host. Next, a stable 
trimer of the E-protein is folded into a hairpin-like structure and forces the target membrane 
to bend towards the viral membrane and eventually fusion takes place [25,27,28]. The fusion 
results in the release of viral RNA into the cytoplasm for initiation of replication and 
translation (Figure 4). 
2.2. The DENV envelope 
The DENV E-glycoprotein induces protective immunity and flavivirus serological 
classification is based on its antigenic variation. During replication the virion assumes three 
conformational states: the immature, mature and fusion-activated form. In the immature 
state, the E-protein is arranged as a heterodimer and generates a “spiky” surface because the 
premembrane protein (prM) covers the fusion peptide. In the Golgi apparatus, the virion 
maturates after a rearrangement of the E-protein. The E-heterodimer transforms to an E-
homodimer and results in a “smoothy” virion surface. After a furin cleavage of the prM to 
pr and M, the virion is fully maturated and can be released from the host cell. Upon fusion, 
the low endosomal pH triggers the rearrangement of the E-homodimer into a trimer [29]. 
The E-protein monomer is composed out of β-barrels organized in three structural domains 
(Figure 5). 
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Figure 4. Schematic overview of the DENV membrane fusion process. (A) Pre-fusion conformation of 
the E-protein consists of homodimers on the virus surface. (B) Low endosomal pH triggers dissociation 
of the E-dimers into monomers which leads to the insertion of the fusion peptide with the endosomal 
target membrane. (C) A stable E-protein trimer is folded in a hairpin-like structure. (D) Hemifusion 
intermediate in which only the outer leaflets of viral and target cellular membranes have fused. (E) 
Formation of the post-fusion E-protein trimer and opening of the fusion pore allows the release of the 
viral RNA into the cytoplasm. Modified from Stiasny et al. [26]. 
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Figure 5. Location of the 2 N-glycans on the envelope protein of DENV. The DENV E-protein dimer 
carries 2 N-glycans on each monomer at Asn67 and Asn153. -strands are shown as ribbons with 
arrows, -helices are shown as coiled ribbons. Thin tubes represent connecting loops. Domain I is 
shown in red, domain II is shown in yellow and contains the fusion peptide near Asn153. Domain III is 
shown in blue. Disulfide bridges are shown in orange. In green, the ligand N-octyl-D-glucoside is 
shown, which interacts with the hydrophobic pocket between domain I and II. Modified from Modis et 
al. [30]. 
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The central domain I contains the aminoterminus and contains two disulfide bridges. 
Domain II is an extended finger-like domain that bears the fusion peptide and stabilizes the 
dimer. This sequence contains three disulfide bridges and is rich in glycine. Between 
domain I and domain II is a binding pocket that can interact with a hydrophobic ligand, the 
detergent β-N-octyl-glucoside. This pocket is an important target for antiviral therapy 
because mutations in this region can alter virulence and the pH necessary for the induction 
of conformational changes. The immunoglobulin-like domain III contains the receptor 
binding motif, the C-terminal domain and one disulfide bond [30,31]. Monoclonal 
antibodies recognizing domain III are the most efficient of blocking DENV [32,33] and this 
domain is therefore an interesting target for antiviral therapy. 
Because dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-
SIGN) (See 1.3.1) is identified as an important receptor for DENV in primary DC in the skin 
and DC-SIGN recognizes high-mannose sugars, carbohydrates present on the E-protein of 
DENV could be important for viral attachment. The E-protein has two potential 
glycosylation sites: asparagines 67 (Asn67) and Asn153. Glycosylation at Asn153 is 
conserved in flaviviruses, with the exception of Kunjin virus, a subtype of West Nile virus 
[34] and is located near the fusion peptide in domain II [30,31] (Figure 5). Glycosylation at 
Asn67 is unique for DENV [31].  
3. Role of DC-SIGN in DENV infection 
Prior to fusion, DENV needs to attach to specific cellular receptors. Because DENV can 
infect a variety of different cell types isolated from different hosts (human, insect, monkey 
and even hamster), the virus must interact with a wide variety of cellular receptors. In the 
last decade, several candidate attachment factor/receptors are identified. DC-SIGN is 
described as the most important human cellular receptor for DENV. 
Since 1977, monocytes are considered to be permissive for DENV infection [35]. More recent, 
phenotyping of peripheral blood mononuclear cells (PBMCs) from pediatric DF and DHF 
cases resulted in the identification of monocytes as DENV target cells [36]. 
First, it was believed that monocytes are important during secondary DENV infections 
during the ADE process, because of their Fc-receptor expression. The complex formed 
between the non-neutralizing antibody and the virus can bind to Fc-receptors and enhance 
infection in neighboring susceptible cells [14,18,37]. However, in vitro, monocytes isolated 
from PBMCs, apparently have a very low susceptibility for DENV infection for reasons that 
remain to be elucidated. 
More detailed observation of the natural DENV infection, changes the idea of monocytes 
being the first target cells. Following intradermal injection of DENV-2 in mice, representing 
the bite of an infected mosquito, DENV occurs to replicate in the skin [38]. The primary 
DENV target cells in the skin are believed to be immature dendritic cells (DC) or 
Langerhans cells [17,39-41]. Immature DC are very efficient in capturing pathogens whereas 
mature DC are relatively resistant to infection. The search for cellular receptors responsible 
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for DENV capture leads to the identification of cell-surface C-type lectin DC-specific 
intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN; CD209) [42-45]. DC-
SIGN is mainly expressed by immature DC, but also alveolar macrophages and interstitial 
DC in the lungs, intestine, placenta and in lymph nodes express DC-SIGN [46]. DC-SIGN is 
a tetrameric transmembrane receptor and is a member of the calcium-dependent C-type 
lectin family. The receptor is composed of four domains: a cytoplasmic domain responsible 
for signaling and internalization due to the presence of a dileucine motif, a transmembrane 
domain, seven to eight extracellular neck repeats implicated in the tetramerization of DC-
SIGN and a carbohydrate recognition domain (CRD) (Figure 6) [47].  
DC-SIGN
N - - C
A B C D
Dendritic cell
 
Figure 6. Structure of DC-SIGN. DC-SIGN, mainly expressed by human dendritic cells in the skin, is 
composed out of four domains: (A) cytoplasmic domain containing internalization signals, (B) 
transmembrane domain, (C) 7 or 8 extracellular neck repeats implicated in the oligomerization of DC-
SIGN and (D) carbohydrate recognition domain which can interact calcium-dependent with a variety of 
pathogens.  
Alen et al. [42] investigated the importance of DC-SIGN receptor in DENV infections using 
DC-SIGN transfected Raji cells versus Raji/0 cells. A strong contrast in DENV susceptibility 
was observed between Raji/DC-SIGN+ cells and Raji/0 cells. DC-SIGN expression renders 
cells susceptible for DENV infection. Also in other cell lines, the T-cell line CEM and the 
astroglioma cell line U87, expression of DC-SIGN renders the cells permissive for DENV 
infection. To evaluate the importance of DC-SIGN, Raji/DC-SIGN+ cells were incubated with 
a specific anti-DC-SIGN antibody prior to DENV infection. This resulted in an inhibition of 
the DENV replication by ~90%, indicating that DC-SIGN is indeed an important receptor for 
DENV. Also 2 mg/ml of mannan inhibited the DENV infection in Raji/DC-SIGN+ cells by 
more than 80%. This data indicate that the interaction between DC-SIGN and DENV is 
dependent on mannose-containing N-glycans present on the DENV envelope [42]. 
Thus, the CRD of DC-SIGN recognizes high-mannose N-glycans and also fucose-containing 
blood group antigens [48,49]. Importantly, DC-SIGN can bind a variety of pathogens like 
human immunodeficiency virus (HIV) [50], hepatitis C virus (HCV) [51], ebola virus [52] 
and several bacteria, parasites and yeasts [46]. Many of these pathogens have developed 
strategies to manipulate DC-SIGN signaling to escape from an immune response [46]. 
Following antigen capture in the periphery, DC maturate by up regulation of the co-
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stimulatory molecules and down regulation of DC-SIGN. By the interaction with ICAM-2 on 
the vascular endothelial cells, DC can migrate to secondary lymphoid organs [53]. Next, the 
activated DC interact with ICAM-3 on naïve T-cells. This results in the stimulation of the T-
cells and subsequently in the production of cytokines and chemokines [54]. Inhibition of the 
initial interaction between DENV and DC could prevent an immune response. DC-SIGN 
could be considered as a target for antiviral therapy by interrupting the viral entry process. 
But caution must be taken into account as the DC-SIGN receptor has also an important role 
in the activation of protective immune responses instead of promoting the viral 
dissemination. However, several DC-SIGN antagonists have been developed such as small 
interfering RNAs (siRNA) silencing DC-SIGN expression [55], specific anti-DC-SIGN 
antibodies [56] and glycomimetics interacting with DC-SIGN [57]. The in vivo effects of DC-
SIGN antagonists remain to be elucidated. 
Besides DC, macrophages play a key role in the immune pathogenesis of DENV infection 
as a source of immune modulatory cytokines [58]. Recently, Miller et al. showed that the 
mannose receptor (MR; CD206) mediates DENV infection in macrophages by recognition 
of the glycoproteins on the viral envelope [59]. Monocyte-derived DC (MDDC) can be 
generated out of monocytes isolated from fresh donor blood incubated IL-4 and GM-
CSF. After a differentiation process MDDC were generated highly expressing DC-SIGN 
(Figure 7A, B) and showing a significantly decrease in CD14 expression in contrast to 
monocytes [59,60]. Again, DC-SIGN expression on MDDC renders cells susceptible for 
DENV in contrast to monocytes (Figure 7A, B). MR is also present on monocyte-derived 
DC (MDDC) and anti-MR antibodies can inhibit DENV infection, although to a lesser 
extent than anti-DC-SIGN antibodies do (Figure 7C) [61]. Furthermore, the combination 
of anti-DC-SIGN and anti-MR antibodies was even more effective in inhibiting DENV 
infection. Yet, complete inhibition of DENV infection was not achieved, indicating that 
other entry pathways are potentially involved. Two other receptors on DC reported to be 
responsible for HIV attachment are syndecan-3 (a member of the heparan sulfate 
proteoglycan family) [62] and the DC immune receptor [63]. Since DENV interacts with 
heparan sulfate, syndecan-3 may be a possible (co)-receptor on DC. It has been 
hypothesized that DENV needs DC-SIGN for attachment and enhancing infection of DC 
in cis and needs MR for internalization [59]. In fact, cells expressing mutant DC-SIGN, 
lacking the internalization domain, are still susceptible for DENV infection because DC-
SIGN can capture the pathogen [43].  
Another C-type lectin, CLEC5A (C-type lectin domain family 5, member A) expressed by 
human macrophages can also interact with DENV and acts as a signaling receptor for the 
release of proinflammatory cytokines [64]. However, whereas the DC-SIGN-DENV 
interaction is calcium-dependent, CLEC5A binding to its ligand is not dependent on 
calcium. Mannan and fucose can inhibit the interaction between CLEC5A and DENV, 
indicating that the interaction is carbohydrate-dependent [64]. However, a glycan array 
demonstrated no binding signal between CLEC5A and N-glycans of mammals or insects 
[65]. The molecular interaction between CLEC5A and DENV remains to be elucidated. 
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Figure 7. Infection of MDDC by DENV. Monocytes isolated from PBMCs were untreated (A) or treated 
with 25 ng/ml IL-4 and 50 ng/ml GM-CSF (B) for 5 days prior to DENV-2 infection. Two days after 
infection the cells were permeabilized and analyzed for DC-SIGN expression and DENV infection by 
confocal microscopy and flow cytometry. Uninfected cells were stained with a PE-labeled monoclonal 
DC-SIGN-antibody (red). Infected cells were stained with a mixture of antibodies recognizing DENV-2 
E-protein and PrM protein (green). Nuclei were stained with DAPI (blue). Infected monocytes (A) and 
MDDC (B) were analyzed by flow cytometry to detect DENV-2 positive cells. The values indicated in 
each dot plot represent the % of DENV-2 positive cells. (C) MDDC were preincubated with 10 µg/ml of 
isotype control IgG2a, anti-DC-SIGN or anti-MR antibody for 30 minutes before DENV-2 infection. Viral 
replication was analyzed by flow cytometry. % Inhibition of viral replication  SEM of 4 different blood 
donors is shown. 
Immune cells, in particular dendritic cells, are the most relevant cells in the discovery of 
specific antiviral drugs against dengue virus, but the isolation of these cells and the 
characterization is unfortunately labour intensive and time consuming.  
Liver/lymph node-specific ICAM-3 grabbing non-integrin (L-SIGN) is a DC-SIGN related 
transmembrane C-type lectin expressed on endothelial cells in liver, lymph nodes and 
placenta [66,67]. Similar to DC-SIGN, L-SIGN is a calcium-dependent carbohydrate-binding 
protein and can interact with HIV [67], HCV [51], Ebola virus [52], West Nile virus [68] and 
DENV [45]. Zellweger et al. observed that during antibody-dependent enhancement in a 
mouse model that liver sinusoidal endothelial cells (LSEC) are highly permissive for 
antibody-dependent DENV infection [69]. Given the fact that LSEC express L-SIGN, it is 
interesting to focus on the role of L-SIGN in DENV infection. L-SIGN expression on LSEC 
has probably an important role in ADE in vivo and therefore it is interesting to find antiviral 
agents interrupting the DENV-L-SIGN interaction and subsequently prevent the 
progression to the more severe and lethal disease DHF/DSS. Although endothelial cells [70] 
and liver endothelial cells [71] are permissive for DENV and L-SIGN-expression renders 
cells susceptible for DENV infection, the in vivo role for L-SIGN in DENV entry remains to 
be established. 
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4. Antiviral therapy 
At present, diagnosis of dengue virus infection is largely clinical, treatment is supportive 
through hydration and disease control is limited by eradication of the mosquito. Many efforts 
have been made in the search for an effective vaccine, but the lack of a suitable animal model, 
the need for a high immunogenicity vaccine and a low reactogenicity are posing huge 
challenges in the dengue vaccine development [7,72]. There are five conditions for a dengue 
vaccine to be effective: (i) the vaccine needs to be protective against all four serotypes without 
reactogenicity, because of the risk of ADE, (ii) it has to be safe for children, because severe 
dengue virus infections often affects young children, (iii) the vaccine has to be economical with 
minimal or no repeat immunizations, because dengue is endemic in many developing 
countries, (iv) the induction of a long-lasting protective immune response is necessary and 
finally (v) the vaccine may not infect mosquitoes by the oral route [7,73]. 
As there is no vaccine available until now, the search for antiviral products is imperative. The 
traditional antiviral approach often attacks viral enzymes, such as proteases and polymerases 
[74,75]. Because human cells lack RNA-dependent polymerase, this enzyme is very attractive 
as antiviral target without cytotoxicity issues. Nucleoside analogues and non-nucleoside 
compounds have previously been shown to be very effective in anti-HIV therapy and anti-
hepatitis B virus therapy. The protease activity is required for polyprotein processing which is 
necessary for the assembly of the viral replication complex. Thereby, the protease is an 
interesting target for antiviral therapy. However, the host cellular system has similar protease 
activities thus cytotoxic effects form a major recurrent problem. Very recently, many efforts 
have been made in the development of polymerase and protease inhibitors of DENV, but until 
today, any antiviral product has reached clinical trials. This chapter is focusing on a different 
step in the virus replication cycle, namely, the viral entry process. In the past few years, 
progression has been made in unraveling the host cell pathways upon DENV infection. It is 
proposed that viral epitopes on the surface of DENV can trigger cellular immune responses 
and subsequently the development of a severe disease. Therefore, these epitopes are potential 
targets for the development of a new class of antiviral products, DENV entry inhibitors. 
Inhibition of virus attachment is a valuable antiviral strategy because it forms the first barrier 
to block infection. Several fusion inhibitors, glycosidase inhibitors and heparin mimetics have 
been described to inhibit DENV entry in the host cell. Here, specific molecules, the 
carbohydrate-binding agents (CBAs), preventing the interaction between the host and the N-
glycans present on the DENV envelope are discussed. 
4.1. Carbohydrate-binding agents (CBAs) 
The CBAs form a large group of natural proteins, peptides and even synthetic agents that 
can interact with glycosylated proteins. CBAs can be isolated from different organisms: 
algae, prokaryotes, fungi, plants, invertebrates and vertebrates (such as DC-SIGN and L-
SIGN) [76,77]. Each CBA will interact in a specific way with monosaccharides, such as 
mannose, fucose, glucose, N-acetylglucosamine, galactose, N-acetylgalactosamine or sialic 
acid residues present in the backbone of N-glycan structures. Because a lot of enveloped 
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viruses are glycosylated at the viral surface, such as HIV, HCV and DENV (Figure 5), CBAs 
could interact with the glycosylated envelope of the virus and subsequently prevent viral 
entry into the host cell [78,79]. Previously, antiviral activity against HIV and HCV [78-80] 
was demonstrated of several CBAs isolated from plants (plant lectins) and algae specifically 
binding mannose and N-acetylglucosamine residues. 
Here, we focus on the antiviral activity of three plant lectins, Hippeastrum hybrid agglutinin 
(HHA), Galanthus nivalis agglutinin (GNA) and Urtica dioica (UDA) isolated from the 
amaryllis, the snow drop and the stinging nettle, respectively. In general, plant lectins form 
a large diverse group of proteins, exhibiting a wide variety of monosaccharide-binding 
properties which can be isolated from different sites within the plant, such as the bulbs, 
leaves or roots. HHA (50 kDa) and GNA (50 kDa) isolated from the bulbs are tetrameric 
proteins. For GNA, each monomer contains two carbohydrate-binding sites and a third site 
is created once if tetramerization had occurred, resulting in a total of 12 carbohydrate-
binding sites (Figure 8). HHA specifically interacts with α1-3 and α1-6 mannose residues 
and GNA only recognizes α1-3 mannose residues. UDA, isolated from the rhizomes of the 
nettle, is active as a monomer containing 2 carbohydrate-binding sites recognizing N-
acetylglucosamine residues (Figure 8). In 1984, UDA was isolated for the first time and with 
its molecular weight of 8.7 kDa, UDA is the smallest plant lectin ever reported [81]. The 
plant lectins have been shown to possess both antifungal and insecticidal activities playing a 
role in plant defense mechanisms. Here, the antiviral activity of the plant lectins against 
DENV will be further highlighted and discussed in detail. 
GNA UDA  
Figure 8. Structure of GNA and UDA. GNA is isolated from the snow drop and is a tetrameric protein. 
UDA is isolated from the stinging nettle and is a monomeric protein composed out of hevein domains. 
Previously, concanavalin A (Con A), isolated from the Jack bean, binding to mannose 
residues and wheat germ agglutinin binding to N-acetylglucosamine (Glc-NAc) residues, 
were shown to reduce DENV infection in vitro. A competition assay, using mannose, proved 
that the inhibitory effect of Con A was due to binding -mannose residues on the viral 
protein, because mannose successfully competed with Con A [82]. Together with the fact 
that HHA, GNA and UDA act inhibitory against HIV and HCV, we hypothesized that these 
plant lectins had antiviral activity against DENV, because DENV has two N-glycosylation 
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sites on the viral envelope and uses DC-SIGN as a cellular receptor to enter DC. The 
antiviral activity of the three plant lectins was investigated in DC-SIGN+ and L-SIGN+ cells 
and the infection was analyzed by flow cytometry, RT-qPCR and confocal microscopy. 
4.2. Broad antiviral activity of CBAs against DENV 
Because DC-SIGN interacts carbohydrate-dependent with DENV, the antiviral activity of 
the three plant lectins, HHA, GNA and UDA, recognizing monosaccharides present in the 
backbone of N-glycans on the DENV E-protein, was evaluated. A consistent dose-dependent 
antiviral activity was observed in DC-SIGN transfected Raji cells against DENV-2 analyzed 
by flow cytometry (detecting the presence of DENV Ag) and RT-qPCR (detecting viral RNA 
in the supernatants) [42].  
Next, the antiviral potency of the three plant lectins was determined against all four 
serotypes of DENV, of which DENV-1 and DENV-4 are low-passage clinical virus isolates, 
in both Raji/DC-SIGN+ cells and in primary immature MDDC. The use of MDDC has much 
more clinical relevance than using a transfected cell line. MDDC resemble DC in the skin 
[83] and mimic an in vivo DENV infection after a mosquito bite. Moreover, cells of the 
hematopoietic origin, such as DC, have been shown to play a key role for DENV 
pathogenesis in a mouse model [84]. A dose-dependent and a DENV serotype-independent 
antiviral activity of HHA, GNA and UDA in MDDC was demonstrated as analyzed by flow 
cytometry (Figure 9). These CBAs proved about 100-fold more effective in inhibiting DENV 
infection in primary MDDC compared to the transfected Raji/DC-SIGN+ cell line.  
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Figure 9. Dose-dependent antiviral activity of HHA, GNA and UDA in DENV-infected MDDC. MDDC 
were infected with the four serotypes of DENV in the presence or absence of various concentrations of 
HHA, GNA and UDA. DENV infection was analyzed by flow cytometry using an anti-PrM antibody 
recognizing all four DENV serotypes (clone 2H2). % of infected cells compared to the positive virus 
control (VC)  SEM of 4 to 12 different blood donors is shown. (Adapted from Alen et al. [61]). 
 
Carbohydrates – Comprehensive Studies on Glycobiology and Glycotechnology 174 
When DENV is captured by DC, a maturation and activation process occurs. DC require 
downregulation of C-type lectin receptors [85], upregulation of costimulatory molecules, 
chemokine receptors and enhancement of their APC function to migrate to the nodal T-
cell areas and to activate the immune system [86]. Cytokines implicated in vascular 
leakage are produced, the complement system becomes activated and virus-induced 
antibodies can cause DHF via binding to Fc-receptors. Several research groups 
demonstrated maturation of DC induced by DENV infection [87,88]. Some groups made 
segregation in the DC population after DENV infection, the infected DC and the 
uninfected bystander cells. They found that bystander DC, in contrast to infected DC, 
upregulate the cell surface expression of costimulatory molecules, HLA and maturation 
molecules. This activation is induced by TNF-α and IFN-α secreted by DENV-infected DC 
[40,89,90]. Instead, Alen et al. observed an upregulation of the costimulatory molecules 
CD80 and CD86 and a downregulation of DC-SIGN and MR on the total (uninfected and 
infected) DC population following DENV infection [61]. This could indicate that the DC 
are activated and can interact with naive T-cells and subsequently activate the immune 
system resulting in increased vascular permeability and fever. When the effect of the 
CBAs was examined on the expression level of the cell surface markers of the total DC 
population, it was shown that the CBAs are able to inhibit the activation of all DC caused 
by DENV and can keep the DC in an immature state. Furthermore, DC do not express 
costimulatory molecules and thus do not interact or significantly activate T-cells. An 
approach to inhibit DENV-induced activation of DC may prevent the immunopathological 
component of DENV disease. 
However, since plant lectins are expensive to produce and not orally bioavailable, the search 
for non-peptidic small molecules is necessary. PRM-S, a highly soluble non-peptidic 
small-size carbohydrate-binding antibiotic is a potential new lead compound in HIV 
therapy, since PRM-S efficiently inhibits HIV replication and prevents capture of HIV to 
DC-SIGN+ cells [91]. PRM-S also inhibited dose-dependently DENV-2 replication in 
MDDC but had only a weak antiviral activity in Raji/DC-SIGN+ cells [61]. Actinohivin 
(AH), a small prokaryotic peptidic lectin containing 114 amino acids, exhibits also anti-
HIV-1 activity by recognizing high-mannose-type glycans on the viral envelope [92]. 
Although DENV has high mannose-type glycans on the E-protein, there was no antiviral 
activity of AH against DENV infection. Other CBAs such as microvirin, griffithsin and 
Banlec have been shown to exhibit potent activity against HIV replication [93-95], but 
these CBAs did not show antiviral activity against DENV. Previously, it has been shown 
that the CBAs HHA, GNA and UDA also target the N-glycans of other viruses, such as 
HIV, HCV [79] and HCMV [80]. This indicates that the CBAs can be used as broad-
spectrum antiviral agents against various classes of glycosylated enveloped viruses. 
Although, the three plant lectins did not act inhibitory against parainfluenza-3, vesicular 
stomatitis virus, respiratory syncytial virus or herpes simplex virus [79]. Together, these 
data indicate a unique carbohydrate-specificity, and thus also a specific profile of antiviral 
activity of the CBAs. 
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4.3. Molecular target of the CBAs on DENV 
It was demonstrated in time of drug addition assays that the mannose binding lectin HHA 
prevents DENV-2 binding to the host cell and acts less efficiently when the virus had 
already attached to the host cell. It was shown that HHA interacts with DENV and not with 
cellular membrane proteins such as DC-SIGN on the target cell. The potency of HHA to 
inhibit attachment of DENV to Raji/DC-SIGN+ cells is comparable to its inhibitory activity of 
the capture of HIV and HCV to Raji/DC-SIGN+ cells [79]. CBAs could thus be considered as 
unique prophylactic agents of DENV infection.  
To identify the molecular target of the CBAs on DENV, a resistant DENV to HHA was 
generated in the mosquito cell line C6/36 by Alen et al. (HHAres DENV). Compared with the 
WT DENV, two highly prevalent mutations were found, namely N67D and T155I, present in 
80% of all clones sequenced. Similar mutational patterns destroying both glycosylation 
motifs (T69I or T69A each in combination with T155I) were present in another 10% of the 
clones analyzed. The N-glycosylation motif 153N-D-T155 is conserved among the majority of 
all flaviviruses, while a second N-glycosylation motif 67N-T-T69 is unique among DENV [96]. 
In the HHAres virus both N-glycosylation motifs were mutated either directly at the actual 
N-glycan accepting a residue of the first site (Asn67) or at the C-proximal Thr155 being an 
essential part of the second N-glycosylation site [97], thus both N-glycosylation sites on the 
viral envelope protein can be considered to be deleted. This indicates that HHA directly 
targets the N-glycans on the viral E-protein. In fact, all clones sequenced showed the 
deletion of the N-glycan at Asn153. However, 10% of the clones sequenced had no mutation 
at the glycosylation motif 67N-T-T69, indicating that this glycosylation motif [96] has a higher 
genetic barrier compared to 153N-D-T155. Though there are multiple escape pathways to 
become resistant to HHA, it seems not to be possible to fully escape the selective pressure of 
favoring a deglycosylation of the viral E-protein. In addition, there were no mutations found 
either apart from the N-glycosylation sites of the E-protein or in any of the five WT DENV-2 
clones passaged in parallel. This is not fully unexpected as flaviviruses replicate with 
reasonable fidelity and DENV does not necessarily exist as a highly diverse quasispecies 
neither in vitro nor in vivo [98,99]. 
There are some contradictions in terms of necessity of glycosylation of Asn67 and Asn153 
during DENV viral progeny. Johnson et al. postulated that DENV-1 and DENV-3 have both 
sites glycosylated and that DENV-2 and DENV-4 have only one N-glycan at Asn-67 [100]. In 
contrast, a study comparing the number of glycans in multiple isolates of DENV belonging 
to all four serotypes led to the consensus that all DENV strains have two N-glycans on the 
E-protein [101]. However, mutant DENV lacking the glycosylation at Asn153 can replicate in 
mammalian and insect cells, indicating that this glycosylation is not essential for viral 
replication [96,102]. There is a change in phenotype because ablation of glycosylation at 
Asn153 in DENV is associated with the induction of smaller plaques in comparison to the 
wild type virus [96]. Asn153 is proximal to the fusion peptide and therefore deglycosylation 
at Asn153 showed also an altered pH-dependent fusion activity and displays a lower 
stability [103,104]. In contrast, Alen et al. showed that the mutant virus, HHAres lacking both 
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N-glycosylation sites, had a similar plaque phenotype in BHK cells (manuscript submitted). 
It has been shown that DENV lacking the glycosylation at Asn67 resulted in a replication-
defective phenotype, because this virus infects mammalian cells weakly and there is a 
reduced secretion of DENV E-protein. Replication in mosquito cells was not affected, 
because the mosquito cells restore the N-glycosylation at Asn67 with a compensatory site-
mutation (K64N) generating a new glycosylation site [96,105]. These data are in contrast 
with other published results, where was demonstrated that DENV lacking the Asn67-linked 
glycosylation can grow efficiently in mammalian cells, depending on the viral strain and the 
amino acid substitution abolishing the glycosylation process [102]. A compensatory 
mutation was detected (N124S) to repair the growth defect without creating a new 
glycosylation site. Thus, the glycan at Asn67 is not necessary for virus growth, but a critical 
role for this glycan in virion release from mosquito cells was demonstrated [102]. However, 
HHA resistant virus was found to replicate efficiently in mosquito and insect cells indicating 
an efficient carbohydrate-independent viral replication in these cell lines. A possible 
explanation for the differences between our data and data from previous studies could be 
that the mutant virus has been generated in mosquito C6/36 cells (during replication under 
antiviral drug pressure) and not in mammalian cells (after introducing the mutations by 
site-directed mutagenesis). In addition, in previous studies, other amino acid substitutions 
were generated, resulting in different virus genotypes and subsequently resulting in poorly 
to predict virus phenotypes.  
The glycosylation at Asn67 is demonstrated to be essential for infection of monocyte-derived 
dendritic cells (MDDC), indicating an interaction between DC-SIGN and the glycan at 
Asn67 [96,106]. Also the HHAres DENV was not able to infect efficiently DC-SIGN+ cells or 
cells that express the DC-SIGN-related liver-specific receptor L-SIGN. Interestingly, MDDC 
are also not susceptible for HHAres DENV infection, indicating the importance of the DC-
SIGN-mediated DENV infection in MDDC. Moreover, cells of the hematopoietic origin, such 
as DC, are described to be necessary for DENV pathogenesis [84]. If the CBA resistant 
DENV in not able to infect DC anymore, it can be stated that the CBAs interfere with a 
physiologically highly relevant target. DC-SIGN is postulated as the most important DENV 
entry receptor until now. The entry process of DENV in Vero, Huh-7, BHK-21 and C6/36 cell 
lines is DC-SIGN-independent and also carbohydrate-independent. Indeed, HHAres DENV 
can efficiently enter and replicate in these cell lines. HHAres DENV lacking both N-glycans 
on the envelope E-glycoprotein is able to replicate efficiently in mammalian cells, with the 
exception of DC-SIGN+ cells. 
The HHAres virus was used as a tool to identify the antiviral target of other classes of 
compounds as it could replicate in human liver Huh-7 cells. The use of Huh-7 cells has 
much more clinical relevance than using monkey (Vero) or hamster (BHK) kidney cells. The 
HHAres DENV was found cross-resistant to GNA, that recognizes like HHA, -1,3 mannose 
residues. UDA, which recognizes mainly the N-acetylglucosamine residues of the N-
glycans, also lacked antiviral activity against HHAres DENV in Huh-7 cells. This indicates 
that the entire backbone of the N-glycan is deleted. Likewise, pradimicin-S (PRM-S), a small-
size -1,2-mannose-specific CBA, was also unable to inhibit HHAres DENV. This 
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demonstrates that PRM-S targets also the N-glycans on the DENV envelope. In contrast, 
ribavirin (RBV), a nucleoside analogue and inhibitor of cellular purine synthesis [74], 
retained as expected wild-type antiviral activity against HHAres DENV. This argues against 
that there would be compensatory mutations in the non-structural proteins of DENV which 
are responsible for an overall enhanced replication of the viral genome [107,108]. SA-17, a 
novel doxorubicine analogue that inhibits the DENV entry process [109], was equipotent 
against WT and HHAres DENV. The SA-17 compound is predicted to interact with the 
hydrophobic binding pocket of the E-glycoprotein which is independent from the N-
glycosylation state of the E-glycoprotein [109]. These data confirm the molecular docking 
experiments of SA-17. 
Generally, the function of glycosylation on surface proteins is proper folding of the protein, 
trafficking in the endoplasmic reticulum, interaction with receptors and influencing virus 
immunogenicity [110]. Virions produced in the mosquito vector and human host may have 
structurally different N-linked glycans, because the glycosylation patterns are 
fundamentally different [101,111]. N-glycosylation in mammalian cells is often of the 
complex-type because a lot of different processing enzymes could add a diversity of 
monosaccharides. Glycans produced in insect cells are far less complex, because of less 
diversity in processing enzymes and usually contain more high-mannose and pauci-
mannose-type glycans. DC-SIGN can distinguish between mosquito- and mammalian cell-
derived alphaviruses [112] and West Nile virus [68], resulting in a more efficient infection by 
a mosquito-derived virus, but this was not the case for DENV [101]. 
Although the CBAs HHA and GNA are not mitogenic and not toxic to mice when 
administered intravenously [113], caution must be taken in the development of the CBAs to 
use as antiviral drug in the clinic. First, the natural plant lectins are expensive to produce 
and hard to scale-up, but efforts have been made to express CBAs in commensal bacteria 
which provide an easy production process of this class of agents. Second, there can be a 
systemic reaction against the lectins such as in food allergies against peanut lectin or banana 
lectin [114,115]. Third, the CBAs can recognize aspecifically cellular glycans and could 
interfere with host cellular processes. But, DENV glycosylation is of the high-mannose or 
pauci-mannose type, which is only rare on mammalian proteins. The synthetic production 
of small non-peptidic molecules, such as PRM-S, with CBA-like activity, could overcome the 
pharmacological problems of the plant lectins. Therefore, PRM-S forms a potential lead 
candidate in the development of more potent and specific DENV entry inhibitors.  
5. Conclusion 
In conclusion, besides active vector control in tropical and subtropical regions, there is an 
urgent need for antiviral treatment to protect half of the world’s population against severe 
DENV infections. DC-SIGN is thought to be the most important DENV receptor and that the 
DC-SIGN-DENV envelope protein interaction is an excellent target for viral entry inhibitors 
such as the CBAs. Resistance against HHA forces the virus to delete its N-glycans and 
subsequently this mutant virus is not able anymore to infect its most important target cells. 
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Thus the CBAs act in two different ways: prevention of viral entry by directly binding N-
glycans on the viral envelope and indirectly forcing the virus to delete its N-glycans and 
loose the capability to infect DC. The plant lectins provided more insight into the entry 
pathway of the virus into the host cell. Hopefully some of these future derivatives with a 
comparable mode of action will reach clinical trials in the near future.  
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